A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic Carcinoma

Pancreatic Carcinoma Clinical Trial

Official title:

Phase I Clinical Trial to Evaluate the Tolerability and Safety of TQB2858 Injection in Subjects With Metastatic Pancreatic Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT05193604
• Other study ID #: TQB2858-I-02
• Status: Terminated
• Phase: Phase 1
• Start date: March 24, 2022
• Est. completion date: November 27, 2023

Study information

• Verified date: January 2023
• Source: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is divided into three phases: single-dose exploration, combination dosage exploration and cohort expansion. The Single-dose exploration stage aims to evaluate the tolerability of TQB2858 injection in subjects with advanced pancreatic carcinoma. The Combination dosage exploration stage aims to evaluate the tolerance of TQB2858 injection combined with chemotherapy in patients with metastatic pancreatic cancer. The cohort expansion phase aims to evaluate the preliminary efficacy of TQB2858 injection combined with gemcitabine, albumin paclitaxel, and with or without anlotinib in patients with metastatic pancreatic cancer，and to explore treatment-related biomarkers.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 29
• Est. completion date: November 27, 2023
• Est. primary completion date: November 27, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• 1. Patients voluntarily joined the study and signed the informed consent;
• 2. Aged: 18 ~ 75 years old;
• 3. Phase 1:patients who have failed to receive at least 1 line of system chemotherapy in the past or the investigator believes that they are not suitable for receiving systemic chemotherapy; The first cohort and second cohort of Phase 2 and of Phase 3: newly diagnosed patients with metastatic pancreatic cancer confirmed by tissue or cytology; The third cohort of Phase 3: patients with metastatic pancreatic cancer who have undergone first-line FOLFIRINOX or FOLFIRINOX+BRCA mutation targeted therapy or PD-1/PD-L1 treatment failure;
• 4. Confirmed to have at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumours (RECIST) 1.1
• 5. Physical condition score( Eastern Cooperative Oncology Group(ECOG) score):

0~1,estimated survival time = 3 months;

• 6. The main organs are functioning normally;
• 7. Women of childbearing age must be negative for serum or urine human chorionic gonadotropin (HCG) within 7 days prior to study enrollment and must be non-lactating; Patients should agree to use contraception during the study period and for 6 months after the study period;

Exclusion Criteria:

• (1) Concomitant disease and medical history:

1. Unmitigated toxic reactions above the Common Terminology Criteria for Adverse Events (CTCAE) grade 1 due to any prior treatment, excluding hair loss and peripheral sensory nerve disorders;;

2. Severe organ failure;

3. Has developed other malignant tumors within 5 years or is currently suffering from the same tumor;

4. Received major surgical treatment or significant traumatic injury (excluding needle biopsy) within 28 days prior to the commencement of study treatment;

5. Long-term unhealed wounds or fractures;

6. Active bleeding or researchers believe that the risk of bleeding is higher;

7. The occurrence of arterial/venous thrombosis events within 6 months, such as cerebrovascular accidents (including temporary ischemic attack, cerebral hemorrhage, cerebral infarction), deep venous thrombosis and pulmonary embolism;

8. People with a history of psychotropic substance abuse and inability to quit or with mental disorders;

9. Symptomatic interstitial lung disease, and conditions that may cause drug pulmonary toxicity or related pneumonia;

10. Subjects with any severe and/or uncontrolled disease;

• (2) Tumor-related symptoms and treatment:

1. Had undergone surgery, chemotherapy, radiation or other anticancer therapy within 4 weeks prior to the start of study treatment (washout period was calculated from the end of the last treatment);

2. Computed tomography (CT) or Magnetic resonance imaging (MRI) shows that the tumor has invaded important blood vessels or the investigator has determined that the tumor is likely to invade important blood vessels and cause fatal hemorrhage during the follow-up study;

3. Patients with brain metastases whose symptoms stabilized less than 4 weeks after discontinuation of dehydrants and steroids;

• (3) Research Treatment Related:

1. Previous history of severe allergy to macromolecular drugs or known components of TQB2858 injection;

2. Participants had participated in other antitumor drug clinical trials in the previous 4 weeks;

3. Have been diagnosed with immunodeficiency or are receiving systemic glucocorticoid therapy or any other form of immunosuppressive therapy (dose of >10mg/ day prednisone or other equivalent efficacy hormone), and continued to use within 2 weeks of the first administration;

4. A history of live attenuated vaccine vaccination within 28 days prior to the study treatment initiation or a planned live attenuated vaccine vaccination during the study period;

5. Study the occurrence of active autoimmune disease requiring systemic treatment (e.g., use of palliative drugs, corticosteroids, or immunosuppressants) within 2 years prior to treatment initiation;

• (4) Participated in other anti-tumor drug clinical trials within 4 weeks before the first medication or less than 5 drug half-lives;
• (5) Subject who, in the Investigator's judgment, has a concomitant disease that seriously endangers the subject's safety or affects the completion of the study, or is considered unsuitable for inclusion for other reasons;

Related Conditions & MeSH terms

• Carcinoma
• Pancreatic Carcinoma
• Pancreatic Neoplasms

Intervention

Drug:
• TQB2858 injection
TQB2858 injection is a programmed cell death 1 ligand 1 (PD-L1)/transforming growth factor-ß bispecific antibody.
• Anlotinib Hydrochloride Capsule
Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
• Gemcitabine hydrochloride for injection
Chemotherapy medicine for metastatic pancreatic cancer
• Paclitaxel for injection (albumin bound)
Chemotherapy medicine for metastatic pancreatic cancer

Locations

Country	Name	City	State
China	The First Affiliated Hospital, Zhejiang University School of Medicine	Hangzhou	Zhejiang

Sponsors (1)

Lead Sponsor	Collaborator
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose limiting toxicity (DLT)	Grade 3 or 4 adverse events related to the study drug that occurred during cycle 1	Baseline up to 3 weeks
Primary	Recommended phase II dose (RP2D)	Recommended dose for phase II	Baseline up to 3 weeks
Primary	Overall response rate (ORR)	ORR refers to the percentage of complete response (CR) or partial response (PR) subjects determined by the investigator based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or iRECIST (CR and PR under iRECIST criteria can occur after imaging disease progression).	Baseline up to 30 weeks
Secondary	Adverse event rate	The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs).	Baseline up to 96 weeks
Secondary	Disease control rate (DCR)	DCR refers to the percentage of subjects with CR, PR, or stable disease (SD) of 6 weeks or more as determined by RECIST 1.1 or iRECIST (CR, PR, SD under iRECIST criteria can occur after imaging disease progression).	Baseline up to 30 weeks
Secondary	Duration of Response (DOR)	DOR will be defined as median number of months from date of first documented objective response until first documented sign of disease progression or death due to any causes.	Baseline up to 30 weeks
Secondary	Progression-Free Survival (PFS)	PFS will be defined as median number of months from the date of randomization until the first documented sign of disease progression or death due to any causes, whichever occurs first.	Baseline up to 30 weeks
Secondary	Overall survival (OS)	From randomization to the time of death from any cause.	Baseline up to 96 weeks